Mirena (Levonorgestrel)

Levonorgestrel is released directly into the uterine cavity, where it binds to progesterone receptors. This action thickens cervical mucus, impairs sperm motility, induces endometrial atrophy to prevent implantation, and may suppress ovulation in some users, thereby providing contraceptive efficacy and reducing menstrual bleeding.

Mirena is supplied as a single intrauterine system containing 52 mg of levonorgestrel, which releases approximately 20 µg of hormone per day. The exact dosing regimen, including insertion timing and duration of use, is determined by the prescribing clinician based on individual patient needs.

Mirena must not be used during pregnancy; if pregnancy occurs, the device should be removed promptly. For breastfeeding women, insertion after delivery is generally considered safe, but clinicians evaluate each case individually. Women should discuss any concerns with their healthcare provider.

To place an order, submit an enquiry on the Mirena product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

The primary alternative is the copper IUD, which provides non‑hormonal contraception. Mirena offers hormonal benefits such as reduced menstrual bleeding and lighter periods, while the copper IUD does not affect bleeding patterns. Choice depends on patient preference, medical history and desired side‑effect profile.

Mirena should be stored at room temperature, preferably below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme temperatures to maintain the integrity of the hormone‑release system until insertion.

Mirena is inserted by a trained healthcare professional into the uterine cavity using a specialized inserter. The procedure is performed in a clinical setting under aseptic conditions, typically after confirming that the patient is not pregnant and has no active pelvic infection.

Serious risks include uterine perforation during insertion, device expulsion or displacement, pelvic inflammatory infection, and the rare possibility of ectopic pregnancy if conception occurs. Prompt medical attention is required if severe abdominal pain, abnormal bleeding or signs of infection develop.

Mirena is contraindicated in women who are currently pregnant, have active pelvic infection, unexplained vaginal bleeding, known or suspected uterine cancer, or severe liver disease. It should also be avoided in individuals with a history of uterine perforation or who are allergic to levonorgestrel.